http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jang Ho Cho(조장호),Ghee-Young Kwon(권기영),Minyong Kang(강민용),Hyun Hwan Sung(성현환),Hwang Gyun Jeon(전황균),Byong Chang Jeong(정병창),Seong Il Seo(서성일),Seong Soo Jeon(전성수),Hyun Moo Lee(이현무),Han-Yong Choi(최한용),Su Ji 대한비뇨기종양학회 2020 대한비뇨기종양학회지 Vol.18 No.3
Purpose: There remains a lot of unmet need to increase understanding of node-positive (ypN+) muscle invasive bladder cancer (MIBC) after neoadjuvant chemotherapy and radical cystectomy to decide the appropriate therapeutics. Materials and Methods: In a retrospective study using the center cancer chemotherapy registry, we found 113 MIBC patients who were treated with neoadjuvant chemotherapy involving gemcitabine and cisplatin (GP) followed by radical cystectomy between 2010 and 2014. Disease-free survival (DFS) and overall survival (OS) were compared according to the pathologic node positivity (ypN- vs. ypN+). Among a total of 165 patients with MIBC who received neoadjuvant chemotherapy involving GP, 118 underwent radical cystectomy. In 46 patients with ypN+ disease, DFS and OS were evaluated according to administration of adjuvant GP. Results: After neoadjuvant chemotherapy and radical cystectomy, 41% of patients had ypN+ disease, which showed significantly shorter DFS (median, 7.4 months; 95% confidence interval [CI], 5.3–9.6 months) and OS (median, 20.0 months; 95% CI, 13.4–26.6 months) compared to those with ypN- disease. The patients with ypN+ disease had a high risk of recurrence or death, regardless of the administration of adjuvant chemotherapy or adjuvant regimen. Conclusions: Within the limitations of this retrospective study, MIBC patients with ypN+ disease despite neoadjuvant chemotherapy and radical cystectomy had a poor prognosis. Further studies involving novel, effective adjuvant treatment including immunotherapy agents are needed to reduce the high risk of recurrence or death in these patients.
김용일(Yong Il Kim),유종우(Chong Woo Yoo),권기영(Ghee Young Kwon) 대한소화기학회 1997 대한소화기학회지 Vol.30 No.4
Lipohyperplasia of the ileocecal valve is a rarely diagnosed lesion of unknown etiology and uncertain significance, which is characterized by diffuse infiltration of mature adipose tissue in the submucosal layer of the ileocecal valve. For endoscopists and radiologists, it has often remained difficult to make a distinction from malignant neoplasia. We describe two cases of lipohyperplasia of the ileocecal valve, all histopathologically diagnosed after major surgery. Case 1 was a 44-year-old male with abdominal distention and epigastric discomfort for two years. Preoperatively villous adenoma with suspicious cancerous changes in the ascending colon was suspected and a right hemicolectomy was performed. Grossly, a tongue-like projection of the enlarged ileocecal valve up to 3*1.5cm was featured microscopically with heavy deposition of mature fat tissue in the subucosal layer. Case 2 was a 33-year-old female with an episode of melena. After radiologic and endoscopic study for Behcets enterocolitis, the right hemicolectomy was performed. Grossly, the ileocecal valve was enlarged up to 3cm and the histologic feature was similar to that of the first case. Through these two cases, we made the conclusion that an appropriate understanding of ileocecal valvular hyperplasia seems to be the first step to make a preoperative histologic diagnosis and prevent oversurgery. (Korean J Gastroenterol 1997; 30:541-546)
심한 증식성 루푸스 신염과 혈전성 혈소판 감소성 자반증이 병발한 남성 환자에서 cyclophosphamide 치료 경험
정혜원 ( Hae Won Jung ),신준암 ( Jun Am Shin ),이유지 ( Yu Ji Lee ),강나리 ( Na Ree Kang ),권기영 ( Ghee Young Kwon ),한봉준 ( Bong Jun Han ),김윤구 ( Yoon Goo Kim ) 대한내과학회 2006 대한내과학회지 Vol.71 No.2
Thrombotic thrombocytopenic purpura is a rare but fatal complication of systemic lupus erythematosus. The diagnosis of thrombotic thrombocytopenic purpura as a syndrome distinct from systemic lupus erythematosus may be challenging particularly when thrombotic thrombocytopenic purpura is presented concomitantly with systemic lupus erythematosus. Early diagnosis and aggressive treatment including plasmapheresis would be required. However, recent reports have suggested that the use of cyclophosphamide may have a role. We describe a patient with systemic lupus erythematosus who was first presented with severe thrombotic thrombocytopenic purpura. Diagnosis was based on typical clinical features of thrombotic thrombocytopenic purpura and laboratory findings of active lupus nephritis. Renal biopsy also confirmed the coexistence of thrombotic thrombocytopenic purpura and diffuse proliferative lupus nephritis. Although prompt extensive plasmapheresis and high dose steroid therapy were performed, oliguric renal failure and thrombocytopenia persisted. After addition of cyclophosphamide to the treatment with plasmapheresis and steroid, clinical manifestations of thrombotic thrombocytopenic purpura and lupus nephritis were markedly improved. (Korean J Med 71:214-218, 2006)
젊은 여자에서 발병한 간질성 신염 포도막염 증후군 1예
김수민 ( Soo Min Kim ),송재욱 ( Jae Uk Song ),최이령 ( E Ryoung Choi ),최희정 ( Hee Joung Choi ),이정은 ( Jung Eun Lee ),권기영 ( Ghee Young Kwon ),허우성 ( Woo Seong Huh ),김윤구 ( Yoon Goo Kim ),김대중 ( Dae Joong Kim ),오하영 ( 대한신장학회 2008 Kidney Research and Clinical Practice Vol.27 No.5
We report a case of adult-onset tubulointerstitial nephritis and uveitis syndrome with Fanconi syndrome. A 31-year-woman presented with fever, anorexia, nausea, general weakness and weight loss for two months. Her initial laboratory findings showed anemia, high serum creatinine, hypouricemia, hypophosphatemia, hypokalemia, glucosuria, and proteinuria. She was diagnosed as having acute tubulointerstitial nephritis by renal biopsy. The etiology of tubulointerstitial nephritis was unclear. She was treated with systemic corticosteroid. Six months later and while the patient was still on systemic corticosteroid (Deflazacort 36 mg), bilateral uveitis developed. Renal function was recovered by systemic corticosteroid and mycophenolic acid. But ocular symptoms relapsed twice despite systemic corticosteroid treatment. The ocular symptoms improved after topical ophthalmic steroid drops and injection. Tubulointerstitial nephritis and uveitis syndrome should be considered in the differential diagnosis of the unexplained tubulointerstitial nephritis. And the need of the steroid treatment also should be considered in the case of adult-onset.
루푸스 신염 관해 유도 치료로서 Mycophenolate Mofetil과 Cyclophosphamide 치료 효과
김용균 ( Yong Kyun Kim ),도연실 ( Yeon Sil Do ),최소연 ( So Yeon Choi ),장은희 ( Eun Hee Jang ),이정은 ( Jung Eun Lee ),차훈석 ( Hoon Suk Cha ),허우성 ( Woo Seong Huh ),김대중 ( Dae Joong Kim ),오하영 ( Ha Young Oh ),권기영 ( Ghee 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.2
목적: 사이클로포스파마이드 (CYC)정맥투여는 활동성 루푸스 신염에서 표준적 치료이나 심각한 독성이 발생할 위험이 높다. 저자들은 활동성 루푸스 신염 환자에서 관해 유도치료로 선택적으로 림프구 증식을 억제하고 독성이 적은 마이코페놀레이트 모페틸 (MMF)치료를 시행하여 CYC 치료와 비교하였다. 방법: 2000년 8월부터 2005년 8월까지 신조직 검사로 활동성 루푸스 신염으로 진단 받고 초기 관해 유도치료로 MMF 치료를 받은 환자 22명과 CYC 정맥투여 치료 받은 환자 28명들을 대상으로 6개월 치료 후 관해율과 부작용을 조사하였다. 완전 관해는 소변 단백 대 크레아티닌 비 (Up/Cr)가 0.3 이하이고 정상 요 침사 소견과 정상 혈청 알부민 수치를 보이며 혈청 크레아티닌이 기저 수치 보다 15% 이상 높지 않는 경우로 정의하였다. 불완전 관해는 Up/Cr가 0.3에서 2.9 사이에 해당되고 혈청 알부민 수치가 적어도 3 g/dL 이상이며 안정된 신기능을 보이는 경우로 정의하였다. 결과: MMF 군은 22명, CYC 군은 28명이었다. 신조직 검사상 class Ⅲ 8명 중 7명은 MMF로, class IV 27명 중 19명은 CYC 정맥투여 치료 했다. MMF 군에서 완전 관해는 7명, 불완전 관해는 10명, 치료 실패는 5명이였으며 CYC 군에서 완전 관해는 11명, 불완전 관해는 11명, 치료 실패는 6명으로 양 치료군 간 차이는 없었다. 4주 간격으로 3회의 CYC 정맥투여 후 MMF 치료로 전환하여 3개월간 관해 유도 치료한 환자는 4명이었으며 치료 후 완전 관해가 2명, 불완전 관해가 1명, 치료 실패가 1명이었다. 부작용은 MMF 군과 CYC 군 사이에 유의한 차이가 없었다. 결론: 활동성 루푸스 신염 환자 초기 관해 유도 치료로서 MMF는 CYC 정맥투여와 비교하여 치료 6개월 후 관해율에 차이가 없었다. 그러나 두 치료군 대상 환자들의 중증도에 차이가 있어 향후 잘 대조된 다수 환자를 대상으로 전향적인 연구가 필요 할 것이다. Purpose: The combination of intravenous cyclophosphamide (CYC) and prednisolone is effective for the treatment of severe lupus nephritis but has serious adverse effects. Mycophenolate mofetil (MMF) Is a new immunosuppressive agent that selectively inhibits activated lymphocytes. This study reports on the clinical experiences at our clinic with MMF and intravenous CYC for the initial induction treatment in patients with lupus nephritis. Methods: 50 patients with lupus nephritis received induction therapy consisting of MMF and prednisolone (n=22) or intravenous CYC and prednisolone (n=28), and followed up for six months. Complete remission was defined as a value for urinary protein: urinary creatinine ratio (Up/Cr) that was less than 0.3, with normal urinary sediment, a normal serum albumin concentration and values for serum creatinine that were no more than 15 percent above the base-line values. Partial remission was defined as a value for Up/Cr that was between 0.3 and 2.9, with a serum albumin concentration of at least 3.0 g/dL. Results: 22 patients treated with MMF and 28 patients with intravenous CYC resulted in complete remission (31.8% vs 39.3%), partial remission (45.5% vs 39.3%) and treatment failure (22.7% vs 21.4 %). Fewer severe infections occurred among patients treated with MMF and prednisolone. Conclusion: As for the induction therapy of lupus nephritis, the combination of MMF and prednisolone may be an effective regimen. However, further randomized, prospective studies are needed to prove the effectiveness of MMF therapy in lupus nephritis.
소간세포암에서 혈관내피세포성장인자의 발현과 재발과의 상관관계
이지현(Ji-Hyun Lee),이광웅(Kwang-Woong Lee),김성주(Sung Ju Kim),최성호(Seong Ho Choi),허진석(Jin Seok Heo),김용일(Yong Il Kim),이환효(Hwan Hyo Lee),박진완(Jin Wan Park),박철근(Cheol Keun Park),권기영(Ghee Young Kwon),조재원(Jae Won J 대한외과학회 2005 Annals of Surgical Treatment and Research(ASRT) Vol.68 No.1